CHICAGO — In this video, Elizabeth S. McDonald, MD, discusses a retrospective, time-dependent cohort study evaluating GLP-1 receptor agonist use and breast cancer risk among women eligible for breast cancer screening.
Results were presented at ASCO Annual Meeting and found significantly lower breast cancer incidence following GLP-1 use.
“Knowing that inflammation is a hallmark of cancer and that these drugs impact inflammation, it’s exciting to think that they could have this preventative effect perhaps not only through how they improve weight loss, but also impacting these other biologic

CHICAGO — In this video, Matthew R. Zibelman, MD, discusses the A-DREAM trial, which found that androgen deprivation therapy interruption resulted in testosterone recovery for two-thirds of patients with metastatic prostate cancer.
Findings were presented at ASCO Annual Meeting.
“While I think larger trials and more data may be necessary to really help us understand the exact frame and guardrails around this type of treatment, I think this does give us leeway to now talk with some of our patients about this possibility and consider breaks in therapy, which I think all will be

ORLANDO — Among African American menthol smokers receiving varenicline plus nicotine replacement therapy, a larger proportion quit after switching to non-menthol cigarettes, according to a poster presented here.
“[Clinicians should] investigate what type of cigarette patients use, with consideration for the area that they live in,” Mindy Conklin, MRT, RRT, ACCS, AE-C, advanced practice respiratory therapist from the VA Medical Center in Maryland, told Healio at the American Thoracic Society International Conference.
In a retrospective chart review, Conklin and colleagues assessed 350 veterans

The time between biopsy and ordering of tissue-based comprehensive genomic profiling varies widely between clinical sites, according to study results.
Delays during this period are the largest contributor to prolonged turnaround time for molecular testing results, which are crucial to inform treatment decisions for people with cancer.
“I would urge anyone working as part of a multidisciplinary team in oncology care to not assume that this testing is happening as quickly as they would hope,” Adam H. Fox, MD, MS, lung cancer pulmonologist at Medical University of South Carolina’s Hollings Cancer

Although nearly a third of individuals with obesity who use GLP-1 receptor agonists experience constipation, the risk for developing constipation among new users appears “quite low,” according to researchers.
“Constipation is one of the most commonly discussed gastrointestinal side effects of GLP-1 receptor agonists, and it is often cited as a reason patients stop therapy,” Kyle Staller, MD, MPH, gastroenterologist and director of the Gastrointestinal Motility Laboratory at Massachusetts General Hospital, told Healio.
Staller and colleagues sought to understand whether GLP-1 use increases the

GLP-1 receptor agonists, particularly new generation agents such as semaglutide and tirzepatide, may significantly reduce the risk for arthroplasty in patients with knee osteoarthritis, data show.
“In musculoskeletal medicine, we are at an early and exciting stage regarding the use of GLP-1s,” Jay V. Karri, MD, MPH, assistant professor of pain medicine at the University of Maryland School of Medicine, told Healio. “The preclinical signals are biologically plausible, but the evidence is still predominantly observational, and prospective trials are needed.”
In a retrospective cohort study, Karri